Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine
Open Access
- 1 March 2009
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 55 (3), 499-504
- https://doi.org/10.1373/clinchem.2008.117143
Abstract
Background: The diagnosis of systemic immunoglobulin light-chain (AL) amyloidosis requires demonstration of amyloid deposits in a tissue biopsy and amyloidogenic monoclonal light chains. The optimal strategy to identify the amyloidogenic clone has not been established. We prospectively assessed the diagnostic sensitivity of the serum free light chain (FLC) κ/λ ratio, a commercial serum and urine agarose gel electrophoresis immunofixation (IFE), and the high-resolution agarose gel electrophoresis immunofixation (HR-IFE) developed at our referral center in patients with AL amyloidosis, in whom the amyloidogenic light chain was unequivocally identified in the amyloid deposits. Methods: The amyloidogenic light chain was identified in 121 consecutive patients with AL amyloidosis by immunoelectron microscopy analysis of abdominal fat aspirates and/or organ biopsies. We characterized the monoclonal light chain by using IFE and HR-IFE in serum and urine and the FLC κ/λ ratio in serum. We then compared the diagnostic sensitivities of the 3 assays. Results: The HR-IFE of serum and urine identified the amyloidogenic light chain in all 115 patients with a monoclonal gammopathy. Six patients with a biclonal gammopathy were omitted from the statistical analysis. The diagnostic sensitivity of commercial serum and urine IFE was greater than that of the FLC κ/λ ratio (96% vs 76%). The combination of serum IFE and the FLC assay detected the amyloidogenic light chain in 96% of patients. The combination of IFE of both serum and urine with the FLC κ/λ ratio had a 100% sensitivity. Conclusions: The identification of amyloidogenic light chains cannot rely on a single test and requires the combination of a commercially available FLC assay with immunofixation of both serum and urine.Keywords
Funding Information
- Fondazione Cariplo
- Ministero della Salute
This publication has 17 references indexed in Scilit:
- Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failureBMC Nephrology, 2008
- Amyloidosis: is a cure possible?Annals of Oncology, 2008
- Evaluation of the serum-free light chain test in untreated patients with AL amyloidosisHaematologica, 2008
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and AmyloidosisAmerican Journal of Hematology, 2005
- Diagnostic Performance of Quantitative κ and λ Free Light Chain Assays in Clinical PracticeClinical Chemistry, 2005
- Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosisAmyloid, 2005
- Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (pts) with metastatic colorectal cancer (MCRC) pretreated with CPT11- or OHP-based CHTJournal of Clinical Oncology, 2004
- Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapyBritish Journal of Haematology, 2003
- Quantitative Analysis of Serum Free Light ChainsAmerican Journal of Clinical Pathology, 2003
- Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosisAmyloid, 2002